Freeline Therapeutics (NASDAQ:FRLN – Get Rating) and Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.
This is a breakdown of current recommendations for Freeline Therapeutics and Eloxx Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation & Earnings
This table compares Freeline Therapeutics and Eloxx Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Freeline Therapeutics||N/A||N/A||-$140.39 million||($3.58)||-0.20|
|Eloxx Pharmaceuticals||N/A||N/A||-$66.73 million||($0.92)||-0.35|
Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Freeline Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Freeline Therapeutics and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Freeline Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals has a beta of 2.47, suggesting that its share price is 147% more volatile than the S&P 500.
Insider and Institutional Ownership
47.1% of Freeline Therapeutics shares are owned by institutional investors. Comparatively, 28.3% of Eloxx Pharmaceuticals shares are owned by institutional investors. 34.6% of Eloxx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Freeline Therapeutics beats Eloxx Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Freeline Therapeutics Company Profile (Get Rating)
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Eloxx Pharmaceuticals Company Profile (Get Rating)
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Freeline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freeline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.